GLP-1R agonists have exhibited potent therapeutic effects on IR [4], providing benefits for the treatment of polycystic ovary syndrome [61], neurological dysfunctions [62], NAFLD, and obesity [63]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.